Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02625857 · ClinicalTrials.gov registry record · Phase 1
Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT02625857 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 26 participants.
The verdict
NCT02625857, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to find and evaluate the recommended Phase 2 dose (RP2D) of JNJ-64041809, a live attenuated double deleted (LADD) Listeria monocytogenes (bacteria in which two virulence genes, which encode molecules that help cause disease, have been removed) when administered intravenously to participants with metastatic castration-resistant prostate cancer (mCRPC).
Interventions
- BIOLOGICAL JNJ-64041809 (Cohort 1A and 1B)
- BIOLOGICAL JNJ-64041809 (Cohort 2A and 2B)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2015-12-10 |
| Est. Completion | 2018-07-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02625857
The ClinicalTrials.gov registry entry for NCT02625857 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which JNJ-64041809 (Cohort 1A and 1B) is the first listed.
NCT02625857 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02625857 about?
NCT02625857 is a clinical study titled "Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer". The purpose of this study is to find and evaluate the recommended Phase 2 dose (RP2D) of JNJ-64041809, a live attenuated double deleted (LADD) Listeria monocytogenes (bacteria in which two virulence genes, which encode molecules that help cause disease, have been removed) when administered intraveno...
What is the current status of trial NCT02625857?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2015-12-10. Estimated completion is 2018-07-03.
What interventions are being tested in trial NCT02625857?
The interventions under investigation include: JNJ-64041809 (Cohort 1A and 1B) (BIOLOGICAL), JNJ-64041809 (Cohort 2A and 2B) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02625857?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.